UNASSIGNED: @entity7102 mediates the life-threatening @entity2657 and blood-brain barrier (BBB) damage that occurs after @entity1779 ( @entity1779 ). We previously found that the selective @entity10027 (CB2R) agonist @entity26405 reduced @entity2657 and @entity51 following germinal @entity548 (GMH). We explored whether CB2R stimulation ameliorated @entity7102 -induced @entity2657 and BBB permeability as well as the possible molecular mechanism involved. A total of 144 Sprague-Dawley (S-D) @entity35 received a @entity7102 (20  U) injection in the right basal ganglia. @entity26405 (1.5  mg/kg) or @entity10029 (3.0  mg/kg) and vehicle were intraperitoneally (i.p.) injected 1  h after surgery. Brain water content measurement, Evans blue (EB) extravasation, Western blot, and immunofluorescence were used to study the effects of a CB2R agonist 24  h after surgery. The results demonstrated that @entity26405 administration significantly decreased @entity7102 -induced @entity2657 and reduced the number of @entity16339 -positive microglia. @entity26405 also decreased the number of @entity10861 /P42(+)/ @entity16339 (+) microglia, lowered @entity5934 , and inhibited the elevated @entity6929 and @entity34499 activities. However, a selective CB2R antagonist ( @entity10029 ) reversed these effects. We demonstrated that CB2R stimulation reduced @entity7102 -induced @entity2657 and @entity75 . We also found that matrix metalloproteinase suppression may be partially involved in these processes.

A XXXX Agonist Prevents @entity7102 -Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in @entity35 .

@entity10027 :: ('57302(Tax:10116)', 'Gene') :: ['cannabinoid receptor 2'] @entity2657 :: ('MESH:D001929', 'Disease') :: ['brain edema', 'cerebral edema'] @entity10029 :: ('MESH:C110630', 'Chemical') :: ['SR-144528'] @entity548 :: ('MESH:D006470', 'Disease') :: ['matrix hemorrhage'] @entity75 :: ('MESH:D001927', 'Disease') :: ['alleviated BBB damage'] @entity16339 :: ('29427(Tax:10116)', 'Gene') :: ['Iba-1'] @entity10861 :: ('50689(Tax:10116)', 'Gene') :: ['P44'] @entity26405 :: ('MESH:C432747', 'Chemical') :: ['JWH-133'] @entity34499 :: ('117033(Tax:10116)', 'Gene') :: ['matrix metallopeptidase (MMP)-12'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficits'] @entity6929 :: ('81687(Tax:10116)', 'Gene') :: ['matrix metallopeptidase (MMP)-9'] @entity7102 :: ('29251(Tax:10116)', 'Gene') :: ['thrombin', 'Thrombin'] @entity5934 :: ('MESH:C536380', 'Disease') :: ['Evans blue extravasation'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['ICH', 'intracerebral hemorrhage']
@entity10027 :: (57302(Tax:10116),Gene) :: ['Cannabinoid Receptor 2']
